



SUPPLEMENTAL MATERIAL


Takayama et al., <http://www.jem.org/cgi/content/full/jem.20100844/DC1>




**Figure S1. Characterization of hiPSCs derived from HDFs.** (A) hESCs (clone KhES-3) or hiPSCs (clone TkDA3-4) were stained with SSEA-4 antibody. TkDA3-4 iPSCs were also treated with isotype IgG control (isotype control). (B) Extracted mRNAs were used for semi-qRT-PCR. HDFs were transduced with retrovirus encoding *OCT3/4*, *SOX2*, *KLF4*, or *c-MYC*, and individual cells harboring one Tg were used as a positive control. HDFs endogenously expressed *KLF4* and *c-MYC* but not *REX1*, *NANOG*, *OCT3/4*, or *SOX2*. (C) Hematoxylin and eosin-stained sections of a teratoma from a NOD/SCID mouse showing variable differentiation lineages derived from three germ layers. (D and E) Southern blot analyses using *OCT3/4* (D) and *c-MYC* (E) cDNA probes. Asterisks indicate the endogenous *OCT3/4* (1.7 kb) or *c-MYC* alleles (2.7 kb). Double asterisks indicate the POU5F1P3 (2.3 kb) and triple asterisks indicate the POU5F1B (3.5 kb). K, kb pairs.




**Figure S2. Human iPSC-derived sac-like structures (iPS-sacs) concentrate multipotent hematopoietic progenitors.** (A) Schematic diagram of the in vitro differentiation protocol for hiPSC-derived hematopoietic cells. Mature hematopoietic cells were generated from cells within the iPS-Sacs on days 14–15. (B) Photomicrographs showing an iPS-Sac on day 15 of culture. Original magnification, 40x. A high-magnification view shows an iPS-Sac containing numerous bright, spherical hematopoietic progenitor cells (arrowheads; 200x). Immunohistochemical staining shows that VEGF-R2 is expressed on the wall of the iPS-Sac. (C) Numbers of colonies arising from  $10^4$  CD34<sup>+</sup> or CD34<sup>-</sup> cells derived from ESCs, TkDN4-M (three-factor clone), TkDA3-2, 3-4, and 3-5 (four-factor clones) on day 15 ( $n = 3$ , means  $\pm$  SEM). (E) Numbers of colonies arising from  $10^4$  hematopoietic progenitors derived from TkDN4-M (three-factor clone) and TkDA3-4 four-factor clone were counted ( $n = 3$ , means  $\pm$  SEM). n, neutrophil; m, macrophage; nm, neutrophil and macrophage; E, erythrocyte; Mix, mixed lineages.




**Figure S3.** Time-dependent changes in the numbers of CD42b (GPIb $\alpha$ )<sup>+</sup> MKs, from days 15 (sac emergence) to 38. MKs were generated from  $10^5$  hematopoietic progenitors within ES- or iPS-Sacs. The number of MKs derived from hESCs on day 22 (7 d after replating) was assigned a value of 1.0 ( $n = 5$ , means  $\pm$  SEM).




**Figure S4.** Hematopoietic progenitors within iPS-Sacs generate mature MKs. Floating cells on day 26 were stained with Write-Giemsa stain. Arrows indicate MKs with polyploidy. Bar, 50  $\mu$ m.



**Figure S5.** Time-dependent changes in the numbers of platelets generated from hESCs or hiPSCs from days 15 to 38. CD41a<sup>+</sup>CD42b<sup>+</sup> platelets were generated from  $10^5$  hematopoietic progenitors within ES- or iPSC-Sacs. The number of CD41a<sup>+</sup>CD42b<sup>+</sup> platelets generated from hESCs on day 22 (7 d after replating) was assigned a value of 1.0 ( $n = 5$ , means  $\pm$  SEM).




**Figure S6. Flow cytometric analysis of platelets derived from hESCs and hiPSCs.** (A) To confirm platelet generation from ESCs or iPSCs, particles in culture dishes were subjected to flow cytometry using the same forward- and side-scatter gates as those used for human plasma-derived adult platelets. Using flow cytometry, adult PB, ESC, and iPSC platelets or c-MYC-transduced ESC platelets were examined for CD42b(GPIb $\alpha$ ) and CD42a(GPIX), along with CD41a. We repeated five times to confirm the gate and expression of CD42b or CD42a. (B) Metalloproteinase inhibition improves in vitro generation of intact CD42b $^{+}$  platelets from human iPSCs. Administration of GM6001, a nonspecific metalloproteinase inhibitor, acted in a concentration-dependent manner to enable restoration of GPIb $\alpha$  expression in human iPSC-platelets. Vehicle, DMSO alone.




**Figure S7. Changes in c-MYC mRNA in several iPSCs.** (A and B) Total RNA was isolated from iPSC cells on days 0, 15, 22, and 26 and analyzed using qPCR. Primers used for c-MYC specifically detect the transcripts from the exogenous (A) or endogenous (B) genes. All expression levels were normalized to the level of *GAPDH* expression. Levels of exogenous c-MYC (A) expression in TkDA3-4-derived mature MKs (day 26) or endogenous c-MYC (B) in undifferentiated TkDA3-4 iPSC clone was assigned a value of 1.0 ( $n = 4$ , means  $\pm$  SEM).







**Figure S8. PAC1 binding and P-selectin expression in platelets derived from ESCs and iPSCs.** (A) Binding of FITC-conjugated PAC-1 to hESC- and hiPSC (four-factor clone)-derived platelets was quantified in the absence or presence of ADP or thrombin using flow cytometry. Some specimens were also incubated with tirofiban to block PAC-1 binding to the integrin  $\alpha\text{IIb}\beta 3$  complex. Administration of ADP induced an increase in PAC-1 binding to both hESC- and hiPSC-derived platelets in a concentration-dependent fashion ( $n = 4$ , means  $\pm$  SEM). (B) Representative P-selectin (CD62P) expression on platelets in the absence or presence of  $50 \mu\text{M}$  ADP. We repeated and confirmed similar tendency of P-selectin expression ( $n = 3$ ).




**Video 1. Time-dependent changes in proplatelet formation from iPSC-derived MKs.**  $10 \mu\text{g/ml}$  of vascular cell adhesion molecule 1 (R&D Systems) was applied to MKs to facilitate platelet generation through  $\alpha 4\beta 1$  integrin ligation (Takizawa, H., K. Eto, A. Yoshikawa, H. Nakauchi, K. Takatsu, and S. Takaki. 2008. *Exp. Hematol.* 36:897–906). Images were taken every 15 min for up to 24 h.




**Video 2. In vivo imaging video of circulating iPSC platelets.** FITC-dextran (green) and  $10^7$  TMRE-stained iPSC platelets (red) were injected, after which mesenteric capillaries were visualized using an in vivo imaging technique. Note the circulating iPSC-platelets (red). Images were reconstructed at  $0.16\times$  speed.



**Video 3. In vivo imaging video of thrombus formation by an iPSC platelet or platelets within blood vessels.** FITC-dextran (green),  $10^7$  TMRE-stained iPSC-platelets (red), and hematoporphyrin were administered. Thrombus formation induced by laser-induced injury in a mesenteric blood vessel is shown. Note the iPS-derived platelets in the developing thrombus (red). Images were reconstructed at 2x speed.



**Video 4. In vivo imaging video of thrombus formation by an iPSC platelet or platelets within blood vessels.** FITC-dextran (green),  $10^7$  TMRE-stained iPSC-platelets (red), and hematoporphyrin were administered. Thrombus formation induced by laser-induced injury in a mesenteric blood vessel is shown. Note the iPS-derived platelets in the developing thrombus (red). Images were reconstructed at 2x speed.



**Video 5. In vivo imaging video of thrombus formation by an iPSC platelet or platelets within blood vessels.** FITC-dextran (green),  $10^7$  TMRE-stained iPSC-platelets (red), and hematoporphyrin were administered. Thrombus formation induced by laser-induced injury in a mesenteric blood vessel is shown. Note the iPS-derived platelets in the developing thrombus (red). Images were reconstructed at 2x speed.

**Table S1.** Primers used in this study

Gene	Primer sequence (5'–3')
<i>c-MYC</i> (Tg)	CAACAACCGAAAATGCACCAGCCCCAG; TACAGGTGGGGTCTTTCATTC
<i>KLF4</i> (Tg)	TGCGGCAAAACCTACACAAAG; TACAGGTGGGGTCTTTCATTC
<i>OCT3/4</i> (Tg)	CAACGAGAGGATTTTGAGGCT; TACAGGTGGGGTCTTTCATTC
<i>SOX2</i> (Tg)	TGCAGTACAACCTCCATGACCA; TACAGGTGGGGTCTTTCATTC
<i>NANOG</i>	CAGCCCCGATTCTCCACCAGTCCC; CGGAAGATTCCAGTCGGGTTCCAC
<i>REX1</i>	CAGATCCTAAACAGCTCGCAGAAT; TATGACTCACTCCAGGGGGCACT
<i>c-MYC</i> (endogenous)	AAGTTTGAGGCAGTTAAAATTATGGCTGAAGC; TGACCTAACTCGAGGAGGAGCTGGAATC
<i>KLF4</i> (endogenous)	TCGCTTCCTCTCTCCGACACA; GCGAACTCACACAGGCGAGAAACC
<i>OCT3/4</i> (endogenous)	TGCGGGCGGACATGGGGAGATCC; TCTTCCACCAGGCCCGGCTC
<i>SOX2</i> (endogenous)	TTGCCTTAAACAAGACCACGAAA; TAGAGCTAGACTCCGGGCGATCC
<i>c-MYC</i> (Tg) for qPCR	TTGCGGAAACGACGAGAACAG; CCCTTTTCTGGAGACTAAATAAA
<i>OCT3/4</i> (Tg) for qPCR	CCCCAGGGCCCCATTTTGGTACC; CCCTTTTCTGGAGACTAAATAAA
<i>SOX2</i> (Tg) for qPCR	ACTTCACATGTCCCAGCACTA; CCCTTTTCTGGAGACTAAATAAA
<i>KLF4</i> (Tg) for qPCR	ATGCGACCGAGCATTTTCCAG; CCCTTTTCTGGAGACTAAATAAA
<i>c-MYC</i> (endogenous) for qPCR	TATTCTGCCCATTTGGGGACA; TTGGTGAAGCTAACGTTGAGG